 Stuart Lind
Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombin | 4 | 2020 | 172 | 1.190 |
Why?
| | Thrombocytopenia | 2 | 2021 | 204 | 1.040 |
Why?
| | Clioquinol | 6 | 2011 | 7 | 0.980 |
Why?
| | Docosahexaenoic Acids | 4 | 2014 | 88 | 0.760 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 25 | 0.670 |
Why?
| | Anticoagulants | 4 | 2018 | 748 | 0.620 |
Why?
| | Copper | 3 | 2010 | 120 | 0.590 |
Why?
| | Antithrombins | 2 | 2020 | 71 | 0.540 |
Why?
| | Infusions, Parenteral | 1 | 2018 | 48 | 0.540 |
Why?
| | Hematologic Tests | 1 | 2017 | 22 | 0.530 |
Why?
| | Drug Monitoring | 2 | 2018 | 401 | 0.490 |
Why?
| | Ionophores | 3 | 2009 | 24 | 0.440 |
Why?
| | Zinc | 5 | 2009 | 307 | 0.430 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 53 | 0.410 |
Why?
| | Thromboplastin | 3 | 2014 | 67 | 0.410 |
Why?
| | Antineoplastic Agents | 6 | 2011 | 2219 | 0.410 |
Why?
| | Vaccination | 1 | 2021 | 1428 | 0.370 |
Why?
| | Blood Coagulation | 4 | 2016 | 274 | 0.350 |
Why?
| | Ceruloplasmin | 2 | 2009 | 10 | 0.330 |
Why?
| | Vitamin B 12 Deficiency | 2 | 2009 | 80 | 0.320 |
Why?
| | Glutathione Peroxidase | 2 | 2007 | 41 | 0.310 |
Why?
| | Superoxide Dismutase | 4 | 2012 | 308 | 0.300 |
Why?
| | Oxyquinoline | 1 | 2009 | 3 | 0.300 |
Why?
| | Apoptosis | 8 | 2012 | 2445 | 0.300 |
Why?
| | Algorithms | 1 | 2017 | 1851 | 0.300 |
Why?
| | Lead Poisoning | 1 | 2009 | 18 | 0.300 |
Why?
| | Erythrocyte Membrane | 1 | 2009 | 55 | 0.290 |
Why?
| | Cell Line, Tumor | 16 | 2015 | 3551 | 0.290 |
Why?
| | Factor Xa Inhibitors | 2 | 2025 | 194 | 0.290 |
Why?
| | Lead | 1 | 2009 | 71 | 0.290 |
Why?
| | Metals | 1 | 2009 | 136 | 0.280 |
Why?
| | Organometallic Compounds | 1 | 2009 | 113 | 0.270 |
Why?
| | Pyridines | 2 | 2009 | 609 | 0.270 |
Why?
| | Pipecolic Acids | 2 | 2020 | 26 | 0.260 |
Why?
| | Gastrectomy | 1 | 2009 | 166 | 0.250 |
Why?
| | Hirudins | 2 | 2020 | 53 | 0.250 |
Why?
| | Lysosomes | 3 | 2015 | 131 | 0.250 |
Why?
| | Metformin | 4 | 2012 | 329 | 0.240 |
Why?
| | Heparin | 3 | 2017 | 247 | 0.240 |
Why?
| | Annexin A5 | 1 | 2005 | 23 | 0.230 |
Why?
| | Peptide Fragments | 3 | 2020 | 697 | 0.230 |
Why?
| | Coagulants | 1 | 2005 | 20 | 0.230 |
Why?
| | Neoplasms | 6 | 2011 | 2913 | 0.220 |
Why?
| | Blood Coagulation Tests | 2 | 2016 | 72 | 0.220 |
Why?
| | Neurodegenerative Diseases | 1 | 2007 | 143 | 0.220 |
Why?
| | Proteolysis | 3 | 2015 | 172 | 0.210 |
Why?
| | Proteasome Inhibitors | 3 | 2015 | 41 | 0.210 |
Why?
| | Protoporphyrins | 2 | 2015 | 16 | 0.210 |
Why?
| | Rivaroxaban | 2 | 2025 | 271 | 0.210 |
Why?
| | Chelating Agents | 3 | 2009 | 76 | 0.200 |
Why?
| | Lipid Peroxidation | 4 | 2014 | 168 | 0.190 |
Why?
| | Heme Oxygenase-1 | 2 | 2014 | 76 | 0.190 |
Why?
| | Cell Survival | 8 | 2012 | 1105 | 0.190 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2014 | 1450 | 0.190 |
Why?
| | Recombinant Fusion Proteins | 1 | 2005 | 666 | 0.190 |
Why?
| | Down-Regulation | 1 | 2004 | 618 | 0.180 |
Why?
| | beta Catenin | 2 | 2015 | 254 | 0.180 |
Why?
| | Breast Neoplasms | 7 | 2012 | 2393 | 0.170 |
Why?
| | Ovarian Neoplasms | 3 | 2013 | 596 | 0.160 |
Why?
| | Humans | 33 | 2025 | 145785 | 0.160 |
Why?
| | Venous Thromboembolism | 1 | 2025 | 328 | 0.160 |
Why?
| | Signal Transduction | 8 | 2013 | 5226 | 0.150 |
Why?
| | Thiones | 2 | 2009 | 13 | 0.150 |
Why?
| | Thrombin Time | 2 | 2020 | 13 | 0.140 |
Why?
| | Superoxide Dismutase-1 | 3 | 2012 | 13 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1969 | 0.130 |
Why?
| | Arginine | 2 | 2020 | 264 | 0.130 |
Why?
| | Blotting, Western | 5 | 2013 | 1184 | 0.130 |
Why?
| | Immunoassay | 1 | 2017 | 109 | 0.130 |
Why?
| | Platelet Activation | 1 | 2017 | 99 | 0.130 |
Why?
| | Cell Proliferation | 4 | 2012 | 2514 | 0.120 |
Why?
| | Postoperative Complications | 1 | 2009 | 2977 | 0.120 |
Why?
| | Catalase | 2 | 2007 | 134 | 0.110 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 981 | 0.110 |
Why?
| | Serotonin | 1 | 2017 | 298 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2020 | 1368 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2008 | 440 | 0.110 |
Why?
| | Thromboembolism | 1 | 2016 | 129 | 0.110 |
Why?
| | Sulfonamides | 2 | 2020 | 583 | 0.110 |
Why?
| | Dabigatran | 1 | 2014 | 30 | 0.100 |
Why?
| | Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 7 | 0.100 |
Why?
| | beta-Alanine | 1 | 2014 | 25 | 0.100 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 43 | 0.100 |
Why?
| | Hospitalization | 2 | 2025 | 2461 | 0.100 |
Why?
| | NF-kappa B | 2 | 2008 | 667 | 0.100 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 212 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 2028 | 0.090 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2011 | 194 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2014 | 189 | 0.090 |
Why?
| | PPAR alpha | 1 | 2012 | 55 | 0.090 |
Why?
| | Caspase 3 | 3 | 2012 | 242 | 0.090 |
Why?
| | Chromans | 1 | 2012 | 25 | 0.090 |
Why?
| | Wnt Proteins | 1 | 2013 | 133 | 0.090 |
Why?
| | Receptors, Steroid | 1 | 2012 | 42 | 0.090 |
Why?
| | Curcumin | 1 | 2012 | 29 | 0.090 |
Why?
| | Mice, Nude | 3 | 2014 | 680 | 0.090 |
Why?
| | Nitroquinolines | 1 | 2011 | 1 | 0.090 |
Why?
| | Receptor, IGF Type 1 | 1 | 2011 | 64 | 0.090 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2012 | 106 | 0.080 |
Why?
| | Biomarkers | 2 | 2018 | 4302 | 0.080 |
Why?
| | Vitamin E | 2 | 2012 | 125 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8347 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2014 | 936 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 298 | 0.080 |
Why?
| | STAT3 Transcription Factor | 1 | 2012 | 206 | 0.080 |
Why?
| | Drug Synergism | 2 | 2012 | 354 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 139 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 241 | 0.070 |
Why?
| | Edetic Acid | 1 | 2009 | 47 | 0.070 |
Why?
| | Buffers | 1 | 2009 | 56 | 0.070 |
Why?
| | Citrates | 1 | 2009 | 41 | 0.070 |
Why?
| | Cell Cycle | 2 | 2009 | 598 | 0.070 |
Why?
| | Protease Inhibitors | 1 | 2009 | 102 | 0.070 |
Why?
| | Ethylenediamines | 1 | 2008 | 7 | 0.070 |
Why?
| | Hydrogen Peroxide | 1 | 2010 | 335 | 0.070 |
Why?
| | Triazenes | 1 | 2008 | 6 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2009 | 138 | 0.070 |
Why?
| | Caspases | 2 | 2009 | 233 | 0.070 |
Why?
| | Adult | 5 | 2025 | 40882 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 223 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2013 | 638 | 0.060 |
Why?
| | Therapeutic Human Experimentation | 1 | 1987 | 2 | 0.060 |
Why?
| | Ethics | 1 | 1987 | 5 | 0.060 |
Why?
| | Ethical Review | 1 | 1987 | 3 | 0.060 |
Why?
| | Human Experimentation | 1 | 1987 | 12 | 0.060 |
Why?
| | Economics | 1 | 1987 | 11 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2007 | 91 | 0.060 |
Why?
| | Financial Support | 1 | 1987 | 18 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2009 | 887 | 0.060 |
Why?
| | Vitamin B 12 | 1 | 2007 | 135 | 0.060 |
Why?
| | Poly(ADP-ribose) Polymerases | 3 | 2012 | 88 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2006 | 86 | 0.060 |
Why?
| | Factor VIIIa | 1 | 2005 | 5 | 0.060 |
Why?
| | Factor X | 1 | 2005 | 26 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2012 | 552 | 0.060 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2005 | 37 | 0.060 |
Why?
| | Phosphatidylserines | 1 | 2005 | 62 | 0.060 |
Why?
| | Cell Growth Processes | 1 | 2005 | 48 | 0.060 |
Why?
| | Aged | 4 | 2025 | 26217 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1361 | 0.050 |
Why?
| | Female | 12 | 2025 | 79045 | 0.050 |
Why?
| | Cisplatin | 1 | 2007 | 345 | 0.050 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2004 | 12 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2009 | 584 | 0.050 |
Why?
| | Regression Analysis | 1 | 2007 | 1001 | 0.050 |
Why?
| | MicroRNAs | 1 | 2010 | 686 | 0.050 |
Why?
| | Blood Vessels | 1 | 2005 | 167 | 0.050 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 611 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2004 | 44 | 0.050 |
Why?
| | Leiomyosarcoma | 1 | 2004 | 29 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 36309 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2005 | 287 | 0.050 |
Why?
| | Research | 1 | 1987 | 431 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2004 | 166 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 855 | 0.050 |
Why?
| | Animals | 5 | 2014 | 38106 | 0.050 |
Why?
| | Prothrombin | 1 | 2003 | 25 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2015 | 155 | 0.050 |
Why?
| | Cattle | 1 | 2005 | 946 | 0.050 |
Why?
| | Pilot Projects | 1 | 2007 | 1898 | 0.040 |
Why?
| | Male | 5 | 2025 | 73012 | 0.040 |
Why?
| | Biomedical Research | 1 | 1987 | 719 | 0.040 |
Why?
| | Hemorrhage | 1 | 2005 | 823 | 0.040 |
Why?
| | Mice | 3 | 2009 | 18358 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 979 | 0.040 |
Why?
| | Microscopy, Fluorescence | 2 | 2013 | 408 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1399 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2007 | 3634 | 0.040 |
Why?
| | Phosphorylation | 2 | 2015 | 1708 | 0.040 |
Why?
| | Amino Acids | 1 | 2003 | 519 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 428 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2003 | 780 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2012 | 456 | 0.030 |
Why?
| | Calibration | 1 | 2016 | 152 | 0.030 |
Why?
| | Antioxidant Response Elements | 1 | 2014 | 7 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 209 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 442 | 0.020 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2014 | 101 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2012 | 19 | 0.020 |
Why?
| | bcl-Associated Death Protein | 1 | 2012 | 10 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2013 | 277 | 0.020 |
Why?
| | Aminosalicylic Acids | 1 | 2012 | 10 | 0.020 |
Why?
| | Prospective Studies | 1 | 2025 | 8078 | 0.020 |
Why?
| | Benzenesulfonates | 1 | 2012 | 23 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 505 | 0.020 |
Why?
| | Pyrazoles | 1 | 2016 | 517 | 0.020 |
Why?
| | Chromones | 1 | 2011 | 43 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 30 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2011 | 149 | 0.020 |
Why?
| | Dasatinib | 1 | 2011 | 58 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2012 | 187 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2012 | 178 | 0.020 |
Why?
| | Trastuzumab | 1 | 2011 | 118 | 0.020 |
Why?
| | Thiazoles | 1 | 2011 | 142 | 0.020 |
Why?
| | Morpholines | 1 | 2011 | 130 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2012 | 184 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2012 | 762 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2010 | 149 | 0.020 |
Why?
| | Base Sequence | 1 | 2013 | 2171 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 319 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 383 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 2009 | 4 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 1247 | 0.020 |
Why?
| | Cathepsin D | 1 | 2009 | 22 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 508 | 0.020 |
Why?
| | Intracellular Membranes | 1 | 2009 | 77 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2009 | 88 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 550 | 0.020 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 192 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14254 | 0.020 |
Why?
| | Pyrimidines | 1 | 2011 | 530 | 0.020 |
Why?
| | Biological Transport | 1 | 2009 | 424 | 0.020 |
Why?
| | Ethics Committees, Clinical | 1 | 1987 | 4 | 0.020 |
Why?
| | Ethics Committees | 1 | 1987 | 4 | 0.020 |
Why?
| | Fees and Charges | 1 | 1987 | 12 | 0.020 |
Why?
| | Research Subjects | 1 | 1987 | 41 | 0.020 |
Why?
| | Ethics Committees, Research | 1 | 1987 | 41 | 0.020 |
Why?
| | Academies and Institutes | 1 | 1987 | 61 | 0.020 |
Why?
| | Organizational Policy | 1 | 1987 | 78 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 878 | 0.010 |
Why?
| | Receptors, Estrogen | 1 | 2009 | 404 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2011 | 883 | 0.010 |
Why?
| | Patient Care | 1 | 1987 | 120 | 0.010 |
Why?
| | Patients | 1 | 1987 | 183 | 0.010 |
Why?
| | Informed Consent | 1 | 1987 | 199 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 992 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 1987 | 171 | 0.010 |
Why?
| | Adolescent | 1 | 2025 | 22577 | 0.010 |
Why?
| | Research Personnel | 1 | 1987 | 185 | 0.010 |
Why?
| | Cell Line | 1 | 2010 | 2823 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2020 | 11794 | 0.010 |
Why?
| | Universities | 1 | 1987 | 445 | 0.010 |
Why?
| | Insurance, Health | 1 | 1987 | 311 | 0.010 |
Why?
| | Data Collection | 1 | 1987 | 643 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 2004 | 187 | 0.010 |
Why?
| | Hospitals | 1 | 1987 | 733 | 0.010 |
Why?
| | Mitochondria | 1 | 2009 | 994 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 4090 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 1987 | 948 | 0.010 |
Why?
| | United States | 1 | 1987 | 16126 | 0.000 |
Why?
|
|
Lind's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|